Zimmer Biomet Holdings (ZBH) is back in focus after recent commentary around its cementless implants and ROSA robotic-assisted surgery platform, along with plans to expand further into upper extremities and foot and ankle categories.

Zimmer Biomet’s recent commentary on cementless implants and ROSA robotics comes as the stock shows a 7.1% 1 month share price return, although the 1 year total shareholder return is down 2.0% and the 3 year total shareholder return is down 36.9%. Recent momentum is therefore building from a weaker long term base.

If Zimmer Biomet’s push into robotics and AI driven surgery interests you, it may be worth scanning the broader opportunity set with the 40 healthcare AI stocks

With Zimmer Biomet trading at US$88.57, sitting at a discount to the average analyst price target and implying a large gap to some intrinsic value estimates, you have to ask: is this a buying opportunity, or is future growth already priced in?

Most Popular Narrative: 10.3% Undervalued

Zimmer Biomet’s most followed narrative places fair value at $98.70 compared with the last close at $88.57, and attributes that gap to execution in robotics, digital platforms, and margins.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Curious what revenue runway, margin lift, and future earnings multiple sit behind that $98.70 figure? The narrative relies on specific growth, profitability, and discount rate assumptions that could influence how you view Zimmer Biomet’s current $88.57 share price.

Result: Fair Value of $98.70 (UNDERVALUED)

However, there are clear watchpoints, including industry pricing pressure that could squeeze margins and integration risks around Paragon 28 and Monogram that may delay expected benefits.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Seen both the optimism and the concerns here and want your own take? Move quickly from headline sentiment to hard data by checking the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

Zimmer Biomet might be your starting point, but the real edge comes from lining up other opportunities side by side using a focused stock screener.

• Target quality at a discount by scanning companies that look mispriced on fundamentals with the 44 high quality undervalued stocks.
• Prioritize resilience by checking stocks that pass strict balance sheet and fundamentals filters using the solid balance sheet and fundamentals stocks screener (48 results).
• Get ahead of the crowd by hunting for underfollowed opportunities through the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.